Biostage (OTCMKTS:BSTG) announced its earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.28), Morningstar.com reports.
Shares of OTCMKTS:BSTG opened at $2.76 on Friday. Biostage has a 12-month low of $0.60 and a 12-month high of $5.85.
ILLEGAL ACTIVITY WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/2018/11/10/biostage-bstg-posts-earnings-results/2971983.html.
Biostage Company Profile
Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.
Further Reading: Technical Analysis
Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.